A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
The purpose of the study is to evaluate the incidence of biopsy confirmed invasive squamous cell carcinoma (SCC) in the selected treatment field (TF) after administration of topical tirbanibulin 10 milligram (mg)/gram (g) ointment or diclofenac sodium 3 percent (%) gel over the 3-year study period.
Keratosis, Actinic
DRUG: Tirbanibulin (KlisyriÂ®) 10 mg/g ointment|DRUG: Diclofenac Sodium 3% Gel
Percentage of Participants with Histologically Confirmed Invasive Squamous Cell Carcinoma (SCC) in the Treatment Field (TF), Percentage of participants with histologically confirmed invasive SCC in the TF will be reported as assessed by dermoscopy., Up to 3 years
Number of Participants With Adverse Events (AEs), An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered an Investigational Product. An AE does not necessarily have a causal relationship with the medicinal product., Up to 3 years|Number of Participants With Serious Adverse Events (SAEs), A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that at any dose, resulted in death, was life-threatening (i.e, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug)., Up to 3 years|Percentage of Participants With any Other Skin Cancer (Other Than SCC) in the TF, Percentage of participants with any other skin cancer (other than SCC) in the TF will be reported., Up to 3 years|Time to Occurrence of Invasive SCC From Baseline in the TF, Time to occurrence of invasive SCC from baseline in the TF will be reported., Up to 3 years|Percentage of Participants Requiring Rescue Treatment After 1 Treatment Course, Percentage of participants requiring rescue treatment after 1 treatment course will be reported., Up to 3 years|Percentage of Participants Requiring Rescue Treatment at Any Time During the Study, Percentage of participants requiring rescue treatment at any time during the study will be reported., Up to 3 years|Percentage of Participants With no Lesions After Treatment of the First Recurrence With Tirbanibulin During the First 52 Weeks, Percentage of participants with no lesions after treatment of the first recurrence with tirbanibulin during the first 52 weeks will be reported., Up to Week 52|Number of Participants With Vital Signs Abnormalities, Number of participants with vital signs (including measurement of heart rate, respiratory rate, systolic and diastolic blood pressure and tympanic temperature) will be reported., Up to 3 years|Number of Participants With Physical Examination Abnormalities, Number of participants with physical examination abnormalities (height, weight and an assessment of head, eyes, ears, nose and throat, integumentary/dermatological, gastrointestinal, cardiovascular, respiratory, musculoskeletal, and neurological systems) will be reported., Up to 3 years
The purpose of the study is to evaluate the incidence of biopsy confirmed invasive squamous cell carcinoma (SCC) in the selected treatment field (TF) after administration of topical tirbanibulin 10 milligram (mg)/gram (g) ointment or diclofenac sodium 3 percent (%) gel over the 3-year study period.